PortalPublikationenTime to disability milestones and annualized relapse rates i...

Time to disability milestones and annualized relapse rates in NMOSD and MOGAD

Standard

Time to disability milestones and annualized relapse rates in NMOSD and MOGAD. / Duchow, Ankelien; Bellmann-Strobl, Judith; Friede, Tim; Aktas, Orhan; Angstwurm, Klemens; Ayzenberg, Ilya; Berthele, Achim; Dawin, Eva; Engels, Daniel; Fischer, Katinka; Flaskamp, Martina; Giglhuber, Katrin; Grothe, Matthias; Havla, Joachim; Hümmert, Martin W; Jarius, Sven; Kaste, Matthias; Kern, Peter; Kleiter, Ingo; Klotz, Luisa; Korporal-Kuhnke, Mirjam; Kraemer, Markus; Krumbholz, Markus; Kümpfel, Tania; Lohmann, Lisa; Ringelstein, Marius; Rommer, Paulus; Schindler, Patrick; Schubert, Charlotte; Schwake, Carolin; Senel, Makbule; Bergh, Florian Then; Tkachenko, Daria; Tumami, Hayrettin; Trebst, Corinna; Vardakas, Ioannis; Walter, Annette; Warnke, Clemens; Weber, Martin S; Wickel, Jonathan; Wildemann, Brigitte; Winkelmann, Alexander; Paul, Friedemann; Stellmann, Jan-Patrick; Häußler, Vivien; Neuromyelitis Optica Study Group (NEMOS).

in: ANN NEUROL, Jahrgang 95, Nr. 4, 04.2024, S. 720-732.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Duchow, A, Bellmann-Strobl, J, Friede, T, Aktas, O, Angstwurm, K, Ayzenberg, I, Berthele, A, Dawin, E, Engels, D, Fischer, K, Flaskamp, M, Giglhuber, K, Grothe, M, Havla, J, Hümmert, MW, Jarius, S, Kaste, M, Kern, P, Kleiter, I, Klotz, L, Korporal-Kuhnke, M, Kraemer, M, Krumbholz, M, Kümpfel, T, Lohmann, L, Ringelstein, M, Rommer, P, Schindler, P, Schubert, C, Schwake, C, Senel, M, Bergh, FT, Tkachenko, D, Tumami, H, Trebst, C, Vardakas, I, Walter, A, Warnke, C, Weber, MS, Wickel, J, Wildemann, B, Winkelmann, A, Paul, F, Stellmann, J-P, Häußler, V & Neuromyelitis Optica Study Group (NEMOS) 2024, 'Time to disability milestones and annualized relapse rates in NMOSD and MOGAD', ANN NEUROL, Jg. 95, Nr. 4, S. 720-732. https://doi.org/10.1002/ana.26858

APA

Duchow, A., Bellmann-Strobl, J., Friede, T., Aktas, O., Angstwurm, K., Ayzenberg, I., Berthele, A., Dawin, E., Engels, D., Fischer, K., Flaskamp, M., Giglhuber, K., Grothe, M., Havla, J., Hümmert, M. W., Jarius, S., Kaste, M., Kern, P., Kleiter, I., ... Neuromyelitis Optica Study Group (NEMOS) (2024). Time to disability milestones and annualized relapse rates in NMOSD and MOGAD. ANN NEUROL, 95(4), 720-732. https://doi.org/10.1002/ana.26858

Vancouver

Duchow A, Bellmann-Strobl J, Friede T, Aktas O, Angstwurm K, Ayzenberg I et al. Time to disability milestones and annualized relapse rates in NMOSD and MOGAD. ANN NEUROL. 2024 Apr;95(4):720-732. https://doi.org/10.1002/ana.26858

Bibtex

@article{a040fa1bd3a4453b83822bd2e594cb95,
title = "Time to disability milestones and annualized relapse rates in NMOSD and MOGAD",
abstract = "OBJECTIVE: To investigate accumulation of disability in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) in a changing treatment landscape. We aimed to identify risk factors for the development of disability milestones in relation to disease duration, number of attacks, and age.METHODS: We analyzed data from individuals with NMOSD and MOGAD from the German Neuromyelitis Optica Study Group registry. Applying survival analyses, we estimated risk factors and computed time to disability milestones as defined by the Expanded Disability Status Score (EDSS).RESULTS: We included 483 patients: 298 AQP4-IgG+ NMOSD, 52 AQP4-IgG-/MOG-IgG- NMOSD patients, and 133 patients with MOGAD. Despite comparable annualized attack rates, disability milestones occurred earlier and after less attacks in NMOSD patients than MOGAD patients (median time to EDSS 3: AQP4-IgG+ NMOSD 7.7 (95% CI 6.6-9.6) years, AQP4-IgG-/MOG-IgG- NMOSD 8.7) years, MOGAD 14.1 (95% CI 10.4-27.6) years; EDSS 4: 11.9 (95% CI 9.7-14.7), 11.6 (95% lower CI 7.6) and 20.4 (95% lower CI 14.1) years; EDSS 6: 20.1 (95% CI 16.5-32.1), 20.7 (95% lower CI 11.6), and 37.3 (95% lower CI 29.4) years; and EDSS 7: 34.2 (95% lower CI 31.1) for AQP4-IgG+ NMOSD). Higher age at onset increased the risk for all disability milestones, while risk of disability decreased over time.INTERPRETATION: AQP4-IgG+ NMOSD, AQP4-IgG-/MOG-IgG- NMOSD, and MOGAD patients show distinctive relapse-associated disability progression, with MOGAD having a less severe disease course. Investigator-initiated research has led to increasing awareness and improved treatment strategies appearing to ameliorate disease outcomes for NMOSD and MOGAD. ANN NEUROL 2024;95:720-732.",
author = "Ankelien Duchow and Judith Bellmann-Strobl and Tim Friede and Orhan Aktas and Klemens Angstwurm and Ilya Ayzenberg and Achim Berthele and Eva Dawin and Daniel Engels and Katinka Fischer and Martina Flaskamp and Katrin Giglhuber and Matthias Grothe and Joachim Havla and H{\"u}mmert, {Martin W} and Sven Jarius and Matthias Kaste and Peter Kern and Ingo Kleiter and Luisa Klotz and Mirjam Korporal-Kuhnke and Markus Kraemer and Markus Krumbholz and Tania K{\"u}mpfel and Lisa Lohmann and Marius Ringelstein and Paulus Rommer and Patrick Schindler and Charlotte Schubert and Carolin Schwake and Makbule Senel and Bergh, {Florian Then} and Daria Tkachenko and Hayrettin Tumami and Corinna Trebst and Ioannis Vardakas and Annette Walter and Clemens Warnke and Weber, {Martin S} and Jonathan Wickel and Brigitte Wildemann and Alexander Winkelmann and Friedemann Paul and Jan-Patrick Stellmann and Vivien H{\"a}u{\ss}ler and {Neuromyelitis Optica Study Group (NEMOS)}",
note = "This article is protected by copyright. All rights reserved.",
year = "2024",
month = apr,
doi = "10.1002/ana.26858",
language = "English",
volume = "95",
pages = "720--732",
journal = "ANN NEUROL",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Time to disability milestones and annualized relapse rates in NMOSD and MOGAD

AU - Duchow, Ankelien

AU - Bellmann-Strobl, Judith

AU - Friede, Tim

AU - Aktas, Orhan

AU - Angstwurm, Klemens

AU - Ayzenberg, Ilya

AU - Berthele, Achim

AU - Dawin, Eva

AU - Engels, Daniel

AU - Fischer, Katinka

AU - Flaskamp, Martina

AU - Giglhuber, Katrin

AU - Grothe, Matthias

AU - Havla, Joachim

AU - Hümmert, Martin W

AU - Jarius, Sven

AU - Kaste, Matthias

AU - Kern, Peter

AU - Kleiter, Ingo

AU - Klotz, Luisa

AU - Korporal-Kuhnke, Mirjam

AU - Kraemer, Markus

AU - Krumbholz, Markus

AU - Kümpfel, Tania

AU - Lohmann, Lisa

AU - Ringelstein, Marius

AU - Rommer, Paulus

AU - Schindler, Patrick

AU - Schubert, Charlotte

AU - Schwake, Carolin

AU - Senel, Makbule

AU - Bergh, Florian Then

AU - Tkachenko, Daria

AU - Tumami, Hayrettin

AU - Trebst, Corinna

AU - Vardakas, Ioannis

AU - Walter, Annette

AU - Warnke, Clemens

AU - Weber, Martin S

AU - Wickel, Jonathan

AU - Wildemann, Brigitte

AU - Winkelmann, Alexander

AU - Paul, Friedemann

AU - Stellmann, Jan-Patrick

AU - Häußler, Vivien

AU - Neuromyelitis Optica Study Group (NEMOS)

N1 - This article is protected by copyright. All rights reserved.

PY - 2024/4

Y1 - 2024/4

N2 - OBJECTIVE: To investigate accumulation of disability in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) in a changing treatment landscape. We aimed to identify risk factors for the development of disability milestones in relation to disease duration, number of attacks, and age.METHODS: We analyzed data from individuals with NMOSD and MOGAD from the German Neuromyelitis Optica Study Group registry. Applying survival analyses, we estimated risk factors and computed time to disability milestones as defined by the Expanded Disability Status Score (EDSS).RESULTS: We included 483 patients: 298 AQP4-IgG+ NMOSD, 52 AQP4-IgG-/MOG-IgG- NMOSD patients, and 133 patients with MOGAD. Despite comparable annualized attack rates, disability milestones occurred earlier and after less attacks in NMOSD patients than MOGAD patients (median time to EDSS 3: AQP4-IgG+ NMOSD 7.7 (95% CI 6.6-9.6) years, AQP4-IgG-/MOG-IgG- NMOSD 8.7) years, MOGAD 14.1 (95% CI 10.4-27.6) years; EDSS 4: 11.9 (95% CI 9.7-14.7), 11.6 (95% lower CI 7.6) and 20.4 (95% lower CI 14.1) years; EDSS 6: 20.1 (95% CI 16.5-32.1), 20.7 (95% lower CI 11.6), and 37.3 (95% lower CI 29.4) years; and EDSS 7: 34.2 (95% lower CI 31.1) for AQP4-IgG+ NMOSD). Higher age at onset increased the risk for all disability milestones, while risk of disability decreased over time.INTERPRETATION: AQP4-IgG+ NMOSD, AQP4-IgG-/MOG-IgG- NMOSD, and MOGAD patients show distinctive relapse-associated disability progression, with MOGAD having a less severe disease course. Investigator-initiated research has led to increasing awareness and improved treatment strategies appearing to ameliorate disease outcomes for NMOSD and MOGAD. ANN NEUROL 2024;95:720-732.

AB - OBJECTIVE: To investigate accumulation of disability in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) in a changing treatment landscape. We aimed to identify risk factors for the development of disability milestones in relation to disease duration, number of attacks, and age.METHODS: We analyzed data from individuals with NMOSD and MOGAD from the German Neuromyelitis Optica Study Group registry. Applying survival analyses, we estimated risk factors and computed time to disability milestones as defined by the Expanded Disability Status Score (EDSS).RESULTS: We included 483 patients: 298 AQP4-IgG+ NMOSD, 52 AQP4-IgG-/MOG-IgG- NMOSD patients, and 133 patients with MOGAD. Despite comparable annualized attack rates, disability milestones occurred earlier and after less attacks in NMOSD patients than MOGAD patients (median time to EDSS 3: AQP4-IgG+ NMOSD 7.7 (95% CI 6.6-9.6) years, AQP4-IgG-/MOG-IgG- NMOSD 8.7) years, MOGAD 14.1 (95% CI 10.4-27.6) years; EDSS 4: 11.9 (95% CI 9.7-14.7), 11.6 (95% lower CI 7.6) and 20.4 (95% lower CI 14.1) years; EDSS 6: 20.1 (95% CI 16.5-32.1), 20.7 (95% lower CI 11.6), and 37.3 (95% lower CI 29.4) years; and EDSS 7: 34.2 (95% lower CI 31.1) for AQP4-IgG+ NMOSD). Higher age at onset increased the risk for all disability milestones, while risk of disability decreased over time.INTERPRETATION: AQP4-IgG+ NMOSD, AQP4-IgG-/MOG-IgG- NMOSD, and MOGAD patients show distinctive relapse-associated disability progression, with MOGAD having a less severe disease course. Investigator-initiated research has led to increasing awareness and improved treatment strategies appearing to ameliorate disease outcomes for NMOSD and MOGAD. ANN NEUROL 2024;95:720-732.

U2 - 10.1002/ana.26858

DO - 10.1002/ana.26858

M3 - SCORING: Journal article

C2 - 38086777

VL - 95

SP - 720

EP - 732

JO - ANN NEUROL

JF - ANN NEUROL

SN - 0364-5134

IS - 4

ER -